ADC Therapeutics SA Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ADC Therapeutics SA (ADCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 515.40 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 66.40K shares, a 79.00% decline year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 449.00K shares, a 859.40% increase year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 486.00K shares, a 17.71% decline year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 173.70K shares, a 66.30% decline year-over-year.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.02M shares, a 37.89% decline from fiscal 2024.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.65M shares, a 57.79% decline from fiscal 2023.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.90M shares, a 32.22% decline from fiscal 2022.
- ADC Therapeutics SA share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 5.75M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 66.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 515.40K shares 10-Q · filed 2026-08-13 | 1.00M shares derived: sum of 3 quarters · filed 2026-08-13 | 1.18M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 449.00K shares 10-Q · filed 2026-05-04 | 935.00K shares derived: sum of 2 quarters · filed 2026-05-04 | 1.11M shares derived: sum of 3 quarters · filed 2026-05-04 | 1.42M shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 486.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 659.70K shares derived: sum of 2 quarters · filed 2026-03-10 | 975.85K shares derived: sum of 3 quarters · filed 2026-03-10 | 1.02M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 173.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 489.85K shares derived: sum of 2 quarters · filed 2025-11-10 | 536.65K shares 10-Q · filed 2025-11-10 | 1.13M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 316.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 362.95K shares 10-Q · filed 2025-08-12 | 953.55K shares derived: sum of 3 quarters · filed 2025-08-12 | 1.47M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 46.80K shares 10-Q · filed 2025-05-14 | 637.40K shares derived: sum of 2 quarters · filed 2025-05-14 | 1.15M shares derived: sum of 3 quarters · filed 2025-05-14 | 1.54M shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 590.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 1.11M shares derived: sum of 2 quarters · filed 2025-03-27 | 1.49M shares derived: sum of 3 quarters · filed 2025-03-27 | 1.65M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 515.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 901.60K shares derived: sum of 2 quarters · filed 2024-11-07 | 1.06M shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 386.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 540.40K shares 10-Q · filed 2024-08-06 | ||
| 2024-03-31 | 154.20K shares 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | 3.90M shares 10-K · filed 2025-03-27 | |||
| 2022-12-31 | 5.75M shares 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |